<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337544</url>
  </required_header>
  <id_info>
    <org_study_id>HNJ-NK-01/2009</org_study_id>
    <nct_id>NCT01337544</nct_id>
  </id_info>
  <brief_title>Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours</brief_title>
  <acronym>NK</acronym>
  <official_title>Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SPANISH HEALTH RESEARCH FUND (FIS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a new antitumor cell therapy for treating childhood refractory
      solid tumours. The aim of this study is explore the graft versus tumour effect mediated by
      allogenic natural killer cells (NKs). NK cell alloreactivity can be predicted by donor killer
      immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I alleles
      mismatch. Cells without an inhibitory HLA ligand may trigger natural killer cell activation
      and elimination of those target cells. Reduced risk of relapsed has been described in
      malignant cancer after haploidentical stem cell transplantation when HLA ligands against the
      inhibitory KIRs present in the donor were absent in the recipient (KIR-HLA receptor-ligand
      mismatch). NK alloreactivity could also be obtained by Natural Killer Receptor (NCR),
      Toll-Like-Receptors (TLRs) and NKG2D receptor stimulation mediated by cytokines or tumour
      cell lines.

      This will be an open, non randomized, Phase I/II clinical trial, with a double objective:
      therapeutic exploratory. The investigators aim at studying safety and efficacy of
      haploidentical stem cell transplantation for the treatment of these malignancies with no cure
      known. Patients will receive an haploidentical stem cell transplantation, followed by IL-15
      stimulated NK cells infusion one month after transplantation. Efficacy of the procedure will
      be evaluated with up-to-date radiological techniques, molecular studies and functional
      assays.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose a new antitumor cell therapy for treating childhood refractory
      solid tumours. The aim of this study is explore the graft versus tumour effect mediated by
      allogenic natural killer cells (NKs). NK cell alloreactivity can be predicted by donor killer
      immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I alleles
      mismatch. Cells without an inhibitory HLA ligand may trigger natural killer cell activation
      and elimination of those target cells. Reduced risk of relapsed has been described in
      malignant cancer after haploidentical stem cell transplantation when HLA ligands against the
      inhibitory KIRs present in the donor were absent in the recipient (KIR-HLA receptor-ligand
      mismatch). NK alloreactivity could also be obtained by Natural Killer Receptor (NCR),
      Toll-Like-Receptors (TLRs) and NKG2D receptor stimulation mediated by cytokines or tumour
      cell lines.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The parents of two patients enrolled who died, presented a claim against the hospital and the
    study was halted.
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events according to NCI-CTC v3.0 CRITERIA as a measure of safety and tolerability</measure>
    <time_frame>Up To 1 Year After Transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate According RECIST V1.1</measure>
    <time_frame>Up To One Year After Transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Childhood Solid Tumor</condition>
  <arm_group>
    <arm_group_label>IL-15 STIMULATED NK CELLS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HAPLOIDENTICAL IL-15 STIMULATED NK CELLS</intervention_name>
    <description>ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)</description>
    <arm_group_label>IL-15 STIMULATED NK CELLS</arm_group_label>
    <other_name>CELL THERAPY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 months to 22 years.

          -  Histological solid tumor confirmation.

          -  Measurable solid tumor by image or molecular techniques.

          -  Solid tumors that have failed to at least 2 chemotherapy protocols.

          -  Suitable haploidentical donor available.

          -  Lansky score &gt; 60%.

        Exclusion Criteria:

          -  Serum bilirubin &gt; 3 mg/dl

          -  GFR &lt; 40 ml/min/1.73 mw

          -  Cardiac left ventricular ejection fraction &lt; 40%

          -  HIV+

          -  Pregnant

          -  Unfavorable psycho-social report.

          -  Antecedent of abandonment treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ANTONIO PEREZ-MARTINEZ, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL UNIVERSITARIO NINO JESUS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Niño Jesus</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.madrid.org/cs/Satellite?pagename=HospitalNinoJesus/Page/HNIJ_home</url>
    <description>HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS</description>
  </link>
  <reference>
    <citation>Pérez-Martínez A, Leung W, Muñoz E, Iyengar R, Ramírez M, Vicario JL, Lassaletta A, Sevilla J, González-Vicent M, Madero L, Díaz-Pérez MA. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer. 2009 Jul;53(1):120-4. doi: 10.1002/pbc.21955.</citation>
    <PMID>19215002</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 25, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>November 8, 2013</last_update_submitted>
  <last_update_submitted_qc>November 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</investigator_affiliation>
    <investigator_full_name>Antonio Perez-Martinez</investigator_full_name>
    <investigator_title>Servicio de Hemato-Oncología Pediátrica</investigator_title>
  </responsible_party>
  <keyword>HAPLOIDENTICAL STEM CELL TRANSPLANTATION</keyword>
  <keyword>NK CELL</keyword>
  <keyword>IL-15</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

